Publication

Epidermal growth factor receptor tyrosine kinase inhibitors.

Ranson, Malcolm R
Citations
Altmetric:
Abstract
Activation of the epidermal growth factor receptor (EGFR) has been linked to tumour proliferation, invasion, metastasis and angiogenesis in epithelial tumours. Inhibitors of the EGFR have emerged as promising anticancer agents and two main approaches have been developed, humanised monoclonal antibodies and tyrosine kinase inhibitors. This review discusses the current status of EGFR tyrosine kinase inhibitors (EGFR-TKIs) that have entered clinical development. EGFR-TKIs are generally well tolerated and can sometimes produce impressive tumour regression in patients with advanced non-small-cell lung cancer. However, highly predictive or surrogate markers of activity have not been identified and there remains a need for translational research in their future development.
Authors
Ranson, Malcolm R
Affiliation
Department of Medical Oncology, University of Manchester, Christie Hospital NHS Trust, Wilmslow Road, Manchester M20 4BX, UK. malcolm.ransom@man.ac.uk
Description
Date
2004-06-14
Publisher
Collections
All Christie Publications
Show all metadata
Keywords
Lung Cancer
Tumour Markers
Type
Article
Citation
Epidermal growth factor receptor tyrosine kinase inhibitors. 2004, 90 (12):2250-5 Br. J. Cancer
Journal Title
Journal ISSN
Volume Title
URI
http://hdl.handle.net/10541/77854
Embedded videos